Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Serotonin 1a (5-HT1a) receptor

2

Sodium-dependent serotonin transporter

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2011

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Major depressive disorder

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Merck

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

CHEBI

2

ChEMBL

2

DAILYMED

2

DRUG BANK

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

PSYCHOANALEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIDEPRESSANTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other antidepressants

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

VILAZODONE

S239O2OOV3

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2011

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Serotonin 1a (5-HT1a) receptor

Sodium-dependent serotonin transporter

Conditions:

Major depressive disorder

Vilazodone is a serotonergic antidepressant. The mechanism of the antidepressant effect of vilazodone is not fully understood but is thought to be related to its inhancement of serotonergic activity in the CNS through selective inhibition of serotoni...

n reuptake. Vilazodone is also a partial agonist at serotonergic 5-HT1A receptors; however, the net result of this action on serotonergic transmission and its role in vilazodone’s antidepressant effect are unknown. The side effects include activation of mania/hypomania in patients with bipolar disorder, seizures can occur with treatment in patients with a seizure disorder.

VILAZODONE HYDROCHLORIDE

U8HTX2GK8J

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2011

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Serotonin 1a (5-HT1a) receptor

Sodium-dependent serotonin transporter

Conditions:

Major depressive disorder

Vilazodone is a serotonergic antidepressant. The mechanism of the antidepressant effect of vilazodone is not fully understood but is thought to be related to its inhancement of serotonergic activity in the CNS through selective inhibition of serotoni...

n reuptake. Vilazodone is also a partial agonist at serotonergic 5-HT1A receptors; however, the net result of this action on serotonergic transmission and its role in vilazodone’s antidepressant effect are unknown. The side effects include activation of mania/hypomania in patients with bipolar disorder, seizures can occur with treatment in patients with a seizure disorder.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1